DCTH
Delcath Systems Inc
Halal Rating :
Last Price
$14.31
Last updated:
Market Cap
-
7D Change
11.88%
1 Year Change
233.57%
Company Overview
Industries
Exchange
Next Earnings Date
Delcath Systems Inc is a biotechnology company focused on developing and commercializing the CHEMOSAT® Hepatic Delivery System/Melphalan/HDS (branded as HEPZATO™ KIT in the United States) for the treatment of primary and metastatic liver cancers. The company's proprietary technology allows for the delivery of high doses of chemotherapeutic drugs directly to the liver while controlling systemic exposure to those drugs.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $11.2m | $12.46m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $7.77m | $11.68m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $3.14m | $13.42m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Delcath Systems Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.